Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results

Author's Avatar
May 10, 2023

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the first quarter ended March 31, 2023, and provided a clinical and business update.